Melvin Churchill - Concepedia

Author

Melvin Churchill

NIHR Leeds Musculoskeletal Biomedical Research Unit ORCID

Also Known As

M Churchill, M. Churchill, Melvin A. Churchill, Melvin Churchill

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

NIHR Leeds Musculoskeletal Biomedical Research Unit University of Pennsylvania Eli Lilly (United States)The University of Queensland University of Leeds

About

Melvin Churchill is an author at NIHR Leeds Musculoskeletal Biomedical Research Unit specializing in medicine, rheumatic diseases, and rheumatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	2.1K
2	Rheumatology	3	3	947
3	Orthopaedics	2	2	557
4	Autoimmune Disease	2	2	739
5	Pathology	1	1	1.2K

Melvin Churchill

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Processing of tumour necrosis factor-α precursor by metalloproteinases A. J. H. Gearing, Paul Beckett, Marika Christodoulou, Nature InflammationMedicineMetalloproteinPathologyCell Death	1994	1.2K
Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis Paul Emery, Roy Fleischmann, Larry W. Moreland, Arthritis & Rheumatism	2009	393
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial Peter Nash, Bruce Kirkham, Masato Okada, The Lancet Rheumatoid DisorderRheumatologySpirit-p2 Phase 3Autoimmune DiseaseMedicine	2017	390
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados, The Lancet InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseSpondyloarthritis	2018	349
Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: Results of a two‐year, randomized, double‐blind, placebo‐controlled trial James R. O’Dell, Robert D. Leff, Gail Paulsen, Arthritis & Rheumatism	2002	322
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler, The Lancet RheumatologySpondyloarthritisRheumatic DiseasesPlacebo-controlled TrialInflammatory Rheumatic Disease	2019	208
Treatment of early Rheumatoid Arthritis with minocycline or placebo. Results of a Randomized, double‐blind, placebo‐controlled trial James R. O’Dell, Claire E. Haire, William Palmer, Arthritis & Rheumatism	1997	178
Treatment of early seropositive rheumatoid arthritis with minocycline: Four-year followup of a double-blind, placebo-controlled trial James R. O’Dell, Gail Paulsen, Claire E. Haire, Arthritis & Rheumatism	1999	131
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis Melvin Churchill, Luis Felipe Flores-Suárez, Mario H. Cardiel, Arthritis Research & Therapy	2013	105
A Randomized Clinical Trial to Evaluate Two Doses of an Intra-Articular Injection of LMWF-5A in Adults with Pain Due to Osteoarthritis of the Knee David Bar‐Or, Kristin Salottolo, Holli Loose, PLoS ONE	2014	48

Page 1